Thromb Haemost 2007; 98(01): 16-19
DOI: 10.1160/TH07-04-0278
Anniversary Issue Contribution
Schattauer GmbH

The discovery of factor X: A personal reminiscence

Fedor Bachmann
1   Prof. Emeritus in Internal Medicine, University of Lausanne, Lausanne, Switzerland
› Author Affiliations
Further Information

Correspondence to:

Fedor Bachmann, MD
Prof. Emeritus in Internal Medicine
University of Lausanne
Lausanne, Switzerland
Chemin de Praz-Mandry 20
1052 Le Mont, Switzerland
Phone: +41 21 652 4515   
Fax: +41 21 653 7788   

Publication History

Received 16 April 2007

Accepted 26 April 2007

Publication Date:
29 November 2017 (online)

 

 


#
  • References

  • 1 Duckert F, Flückiger P, Matter M, Koller F. Clotting Factor X. Physiological and physicochemical properties. Proc Soc ExpBiolMed 1955; 99: 17-22.
  • 2 AleX ander B, de Vries A, Goldstein R. A factor in serum which accelerates the conversion of prothrombin to thrombin. II. Its evolution with special reference to the influence of conditions which affect blood coagulation. Blood 1949; 4: 739-746.
  • 3 AleX ander B, Goldstein R, Landwehr G. et al. Congenital SPCA deficiency: a hitherto unrecognized coagulation defect with hemorrhage rectified by serum and serum fractions. J Clin Invest 1951; 30: 596-608.
  • 4 Owren PA. Proconvertin, the new clotting factor. Scand J Clin Lab Invest 1951; 3: 168.
  • 5 Koller F, Loeliger A, Duckert F. Experiments on a new clotting factor (Factor VII). Acta haematol 1951; 6: 1-18.
  • 6 Koller F. Citation Classic - experiments on a new clotting factor (Factor VII). Current Contents/Life Sci 1984; 43: 18.
  • 7 Owren PA. Le complexe activateur de la prothrombine et son intérêt clinique. Rev Hematol 1951; 6: 135-147.
  • 8 Owren PA. The control of dicoumarol therapy and the quantitative determination of proconvertin. Scand J Clin Lab Invest 1951; 3: 201-208.
  • 9 Biggs R, Douglas AS. The thromboplastin generation test. J Clin Path 1953; 6: 23-29.
  • 10 Graham GB. Stuart factor. Discovery and designation as Factor X. J Thromb Haemost 2003; 1: 871-872.
  • 11 Hougie C. The discovery of Factor X. J Thromb Haemost 2004; 2: 189-191.
  • 12 Denson KWE. The discovery of Factor X. J Thromb Haemost 2004; 2: 188-189.
  • 13 Telfer TP, Denson KW, Wright DR. A“new” coagulation defect. Br J Haematol 1956; 1: 308-316.
  • 14 Hougie C. Effect of Russel’s viper venom (Stypven) on Stuart clotting defect. Proc Soc Exp Biol Med 1956; 93: 570-573.
  • 15 Hougie C, Graham JB. The blood clotting role and mode of inheritance of the Stuart factor. Proc 6th congr. Int Soc Haematol, 1956: 327 Abstract.
  • 16 Hougie C, Barrow HM, Graham JB. Stuart clotting defect. I. Segregation of an hereditary hemorrhagic state from the heterogeneous group heretofore called “stable factor”, (SPCA, proconvertin, Factor VII) deficiency. J Clin Invest 1957; 36: 485-496.
  • 17 Graham GB, Barrow E, Hougie C. Stuart clotting defect. II. Genetic aspects of a “new” hemorrhagic state. J Clin Invest 1957; 36: 497-503.
  • 18 Flückiger P, Hitzig WH, Bachmann F, Duckert F. Hämorrhagische Diathese, bedingt durch kongenitalen Mangel eines neuen Gerinnungsfaktors (Prower-Stuart-Factor). Helv Paediatr Acta 1957; 12: 260-270.
  • 19 Bachmann F, Duckert F, Flückiger P, Hitzig W, Koller F. Ueber einen neuartigen kongenitalen Gerinnungsdefect (Mangel an Stuart Faktor). Thromb Diath Haemorrh 1957; 1: 87-92.
  • 20 Bachmann F, Duckert F, Geiger M, Baer P, Koller F. Differentiation of the Factor VII complex. Studies on the Stuart-Prower factor. Thromb Diath Haemorrh 1957; 1: 169-194.
  • 21 Bachmann F. Mode of inheritance of Factor X deficiency. International Committee on Blood Clotting Factors, Amsterdam. Thromb Diath Haemorrh 1965; (Suppl) 17: 191-199.
  • 22 Bachmann F, Duckert F, Koller F. The Stuart-Prower factor assay and its clinical significance. Thromb Diath Haemorrh 1958; 2: 24-38.
  • 23 Bachmann F. Citation Classic - The Stuart-Prower factor assay and its clinical significance. Current Contents/Life Sci 1981; 13: 19.
  • 24 Bachmann F. Familienuntersuchungen beim kongenitalen Stuart-Prower-Faktor-Mangel. Arch Julius Klaus-Stiftung 1958; 23: 27-78.

Correspondence to:

Fedor Bachmann, MD
Prof. Emeritus in Internal Medicine
University of Lausanne
Lausanne, Switzerland
Chemin de Praz-Mandry 20
1052 Le Mont, Switzerland
Phone: +41 21 652 4515   
Fax: +41 21 653 7788   

  • References

  • 1 Duckert F, Flückiger P, Matter M, Koller F. Clotting Factor X. Physiological and physicochemical properties. Proc Soc ExpBiolMed 1955; 99: 17-22.
  • 2 AleX ander B, de Vries A, Goldstein R. A factor in serum which accelerates the conversion of prothrombin to thrombin. II. Its evolution with special reference to the influence of conditions which affect blood coagulation. Blood 1949; 4: 739-746.
  • 3 AleX ander B, Goldstein R, Landwehr G. et al. Congenital SPCA deficiency: a hitherto unrecognized coagulation defect with hemorrhage rectified by serum and serum fractions. J Clin Invest 1951; 30: 596-608.
  • 4 Owren PA. Proconvertin, the new clotting factor. Scand J Clin Lab Invest 1951; 3: 168.
  • 5 Koller F, Loeliger A, Duckert F. Experiments on a new clotting factor (Factor VII). Acta haematol 1951; 6: 1-18.
  • 6 Koller F. Citation Classic - experiments on a new clotting factor (Factor VII). Current Contents/Life Sci 1984; 43: 18.
  • 7 Owren PA. Le complexe activateur de la prothrombine et son intérêt clinique. Rev Hematol 1951; 6: 135-147.
  • 8 Owren PA. The control of dicoumarol therapy and the quantitative determination of proconvertin. Scand J Clin Lab Invest 1951; 3: 201-208.
  • 9 Biggs R, Douglas AS. The thromboplastin generation test. J Clin Path 1953; 6: 23-29.
  • 10 Graham GB. Stuart factor. Discovery and designation as Factor X. J Thromb Haemost 2003; 1: 871-872.
  • 11 Hougie C. The discovery of Factor X. J Thromb Haemost 2004; 2: 189-191.
  • 12 Denson KWE. The discovery of Factor X. J Thromb Haemost 2004; 2: 188-189.
  • 13 Telfer TP, Denson KW, Wright DR. A“new” coagulation defect. Br J Haematol 1956; 1: 308-316.
  • 14 Hougie C. Effect of Russel’s viper venom (Stypven) on Stuart clotting defect. Proc Soc Exp Biol Med 1956; 93: 570-573.
  • 15 Hougie C, Graham JB. The blood clotting role and mode of inheritance of the Stuart factor. Proc 6th congr. Int Soc Haematol, 1956: 327 Abstract.
  • 16 Hougie C, Barrow HM, Graham JB. Stuart clotting defect. I. Segregation of an hereditary hemorrhagic state from the heterogeneous group heretofore called “stable factor”, (SPCA, proconvertin, Factor VII) deficiency. J Clin Invest 1957; 36: 485-496.
  • 17 Graham GB, Barrow E, Hougie C. Stuart clotting defect. II. Genetic aspects of a “new” hemorrhagic state. J Clin Invest 1957; 36: 497-503.
  • 18 Flückiger P, Hitzig WH, Bachmann F, Duckert F. Hämorrhagische Diathese, bedingt durch kongenitalen Mangel eines neuen Gerinnungsfaktors (Prower-Stuart-Factor). Helv Paediatr Acta 1957; 12: 260-270.
  • 19 Bachmann F, Duckert F, Flückiger P, Hitzig W, Koller F. Ueber einen neuartigen kongenitalen Gerinnungsdefect (Mangel an Stuart Faktor). Thromb Diath Haemorrh 1957; 1: 87-92.
  • 20 Bachmann F, Duckert F, Geiger M, Baer P, Koller F. Differentiation of the Factor VII complex. Studies on the Stuart-Prower factor. Thromb Diath Haemorrh 1957; 1: 169-194.
  • 21 Bachmann F. Mode of inheritance of Factor X deficiency. International Committee on Blood Clotting Factors, Amsterdam. Thromb Diath Haemorrh 1965; (Suppl) 17: 191-199.
  • 22 Bachmann F, Duckert F, Koller F. The Stuart-Prower factor assay and its clinical significance. Thromb Diath Haemorrh 1958; 2: 24-38.
  • 23 Bachmann F. Citation Classic - The Stuart-Prower factor assay and its clinical significance. Current Contents/Life Sci 1981; 13: 19.
  • 24 Bachmann F. Familienuntersuchungen beim kongenitalen Stuart-Prower-Faktor-Mangel. Arch Julius Klaus-Stiftung 1958; 23: 27-78.